Stock Details
BIIB is Biogen Inc.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 202.36$. Average daily volumn in 3 months 1.14M. Market cap 31.58B

Stock symbol : BIIB. Exchange : NasdaqGS. Currency : USD
Lastest price : 215.65$. Total volume : 14.61k. Market state REGULAR
Click reload if you want to check the lastest price on market!!!

Biogen Inc. (BIIB)
Last Price

Previous Close215.98
Day Range215.40-215.90
Bid215.10 x 800
Ask220.80 x 900
Average Volume1.14M
Market Cap31.58B
52 Week Range187.16-372.12
Trailing P/E21.87
Foward P/E13.48
Dividend (Yield %)N/A
Ex-Dividend DateN/A

Financial Details

According to Biogen Inc.'s financial reports the company's revenue in 2021 were 10.98B an decrease(-23.08%) over the years 2020 revenue that were of 13.44B. In 2021 the company's total earnings were 1.56B while total earnings in 2020 were 4B(-75%).

Loading ...


Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXAB... I, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Market Cap:
Total Assets:
Total Cash:

News about "Biogen Inc."


Biogen Inc. stock outperforms competitors on strong trading day

Source from : MarketWatch - 23 hours ago

Shares of Biogen Inc. advanced 1.60% to $215.98 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P ...See details»


The Petri Dish: FDA to fast-track Biogen's next Alzheimer's drug

Source from : The Business Journals - 11 hours ago

The FDA has given priority review to lecanemab, the second Alzheimer's disease drug made by Biogen and Japanese pharmaceutical firm Eisai, under the accelerated approval pathway — the same regulatory ...See details»


Biogen’s Alzheimer’s drug will get priority review in US

Source from : The Boston Globe - 1 days ago

The Food and Drug Administration accepted the application under the accelerated approval pathway and is expected to complete the review by Jan. 6, the companies said in a statement.See details»


FDA decision on Eisai, Biogen Alzheimer's drug due in January

Source from : Reuters - 1 days ago

The U.S. Food and Drug Administration will expedite its review of Eisai Co Ltd's and Biogen Inc's experimental Alzheimer's drug lecanemab, with a decision due by Jan 6, 2023, the companies said on ...See details»


Biogen Inc. (NASDAQ:BIIB) Shares Sold by Wedbush Securities Inc.

Source from : Defense World - 2 days ago

Wedbush Securities Inc. lowered its position in shares of Biogen Inc. (NASDAQ:BIIB – Get Rating) by 27.5% during the first quarter, Holdings Channel reports. The fund owned 1,832 shares of the ...See details»


Xponance Inc. Acquires 364 Shares of Biogen Inc. (NASDAQ:BIIB)

Source from : Defense World - 4 days ago

Xponance Inc. grew its holdings in Biogen Inc. (NASDAQ:BIIB – Get Rating) by 3.9% in the first quarter, HoldingsChannel reports. The fund owned 9,791 shares of the biotechnology company’s stock after ...See details»


Can Biogen’s backup plan for Alzheimer’s succeed?

Source from : The Boston Globe on - 3 days ago

Biogen and its partner Eisai have submitted another Alzheimer’s therapy to the FDA. But just as before, experts are divided on the drug.See details»


EXCLUSIVE: Has Biotech Bottomed? NYSE Executive Floor Director Says Biogen And These 3 Stocks Look Poised To Outperform

Source from : Business Insider - 7 days ago

Markets continue to trend lower amid rising inflation and Fed uncertainty, but one New York Stock Exchange floor director says the bottom may be in for a couple of beaten-down sectors.See details»


Biogen to reimburse employees who travel 100-plus miles for abortion

Source from : The Business Journals - 8 days ago

In the immediate aftermath of the Supreme Court's decision to overturn nationwide protections for abortion, Cambridge-based Biogen Inc. says it will begin paying for travel for its employees to access ...See details»


Ritholtz Wealth Management Sells 233 Shares of Biogen Inc. (NASDAQ:BIIB)

Source from : ETF Daily News - 7 days ago

Ritholtz Wealth Management lowered its holdings in Biogen Inc. (NASDAQ:BIIB – Get Rating) by 17.9% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The ...See details»

Biogen stops clinical trial tracking Aduhelm

Source from : MarketWatch on - 13 days ago

Biogen Inc. said in a statement that it stopped a post-marketing clinical trial testing its Alzheimer's disease therapy Aduhelm, citing a Medicare policy that will limit usage of the drug. The company ...See details»


IBM Retirement Fund Trims Stock Position in Biogen Inc. (NASDAQ:BIIB)

Source from : ETF Daily News - 10 days ago

IBM Retirement Fund lessened its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Get Rating) by 5.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the ...See details»

Biogen, Eisai's Alzheimer's therapy lecanemab gets FDA priority review

Source from : Seeking Alpha - 1 days ago

The U.S. Food and Drug Administration (FDA) granted priority review to Biogen (BIIB) and Eisai's (ESALY) (ESALF) lecanemab to treat mild cognitive impairment ((MCI)) due ...See details»


Pharmalittle: Some scientists want more Vertex CRISPR data; Biogen Alzheimer’s drug to get priority review

Source from : STAT - 1 days ago

The FDA will expedite its review of Biogen's and Eisai's experimental Alzheimer's drug lecanemab, with a decision due by Jan. 6, 2023, the companies said.See details»